NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL ...
This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia’s RESOLVE trial. At 36 weeks, patients in Cohort ...
New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib[1] ...
CVR Energy retains the option to restart renewable diesel production if future policy or economics warrant, but current plans ...
Mips AB, the Stockholm, Sweden-based helmet safety technology company, reported a strong start to 2026, delivering organic ...
Click Therapeutics cuts 25 employees days after securing $50M from Boehringer Ingelheim. Company cites transition from R&D to ...
Good morning, everyone, and welcome to HCSG's Second Quarter 2025 Earnings Call. With me today are Matt McKee, our Chief ...
Today, the Council for Innovation Promotion (C4IP) published the third edition of its Congressional Innovation Scorecard, ...
Following the elimination of foreign exchange (FX) exposure that had impacted negatively on its performance in recent years, ...
What are people in consensually nonmonoagmous relationships doing to combat stigma and discrimination? Grassroots organizing!
Get all latest & breaking news on Opening Bell. Watch videos, top stories and articles on Opening Bell at moneycontrol.com.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results